175 related articles for article (PubMed ID: 37870954)
21. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
22. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
Osdoit M; Yau C; Symmans WF; Boughey JC; Ewing CA; Balassanian R; Chen YY; Krings G; Wallace AM; Zare S; Fadare O; Lancaster R; Wei S; Godellas CV; Tang P; Tuttle TM; Klein M; Sahoo S; Hieken TJ; Carter JM; Chen B; Ahrendt G; Tchou J; Feldman M; Tousimis E; Zeck J; Jaskowiak N; Sattar H; Naik AM; Lee MC; Rosa M; Khazai L; Rendi MH; Lang JE; Lu J; Tawfik O; Asare SM; Esserman LJ; Mukhtar RA
JAMA Surg; 2022 Nov; 157(11):1034-1041. PubMed ID: 36069821
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
24. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen Acceptance and Adherence among Patients with Ductal Carcinoma In Situ (DCIS) Treated in a Multidisciplinary Setting.
Karavites LC; Kane AK; Zaveri S; Xu Y; Helenowski I; Hansen N; Bethke KP; Rasmussen-Torvik LJ; Khan SA
Cancer Prev Res (Phila); 2017 Jul; 10(7):389-397. PubMed ID: 28559459
[TBL] [Abstract][Full Text] [Related]
28. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
Petrelli F; Barni S
Radiother Oncol; 2011 Aug; 100(2):195-9. PubMed ID: 21411161
[TBL] [Abstract][Full Text] [Related]
30. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
31. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Chen YY; DeVries S; Anderson J; Lessing J; Swain R; Chin K; Shim V; Esserman LJ; Waldman FM; Hwang ES
BMC Cancer; 2009 Aug; 9():285. PubMed ID: 19689789
[TBL] [Abstract][Full Text] [Related]
32. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
[TBL] [Abstract][Full Text] [Related]
34. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM
Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
[TBL] [Abstract][Full Text] [Related]
36. Clinical Trials for Ductal Carcinoma In Situ of the Breast.
Han MS; Khan SA
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):293-301. PubMed ID: 30206737
[TBL] [Abstract][Full Text] [Related]
37. Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast.
Lazzeroni M; Puntoni M; Provinciali N; Webber TB; Briata IM; D'Amico M; Giuliano S; Siri G; Cagnacci S; DeCensi A
Breast; 2019 Nov; 48 Suppl 1():S39-S43. PubMed ID: 31839158
[TBL] [Abstract][Full Text] [Related]
38. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Sestak I; Smith SG; Howell A; Forbes JF; Cuzick J
Ann Oncol; 2018 Feb; 29(2):504-509. PubMed ID: 29126161
[TBL] [Abstract][Full Text] [Related]
39. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
40. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Caviglia S; Avino F; Cortesi L; Taverniti C; Pacquola MG; Falcini F; Gulisano M; Digennaro M; Cariello A; Cagossi K; Pinotti G; Lazzeroni M; Serrano D; Branchi D; Campora S; Petrera M; Buttiron Webber T; Boni L; Bonanni B
J Clin Oncol; 2019 Jul; 37(19):1629-1637. PubMed ID: 30973790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
